ESSA Pharma
EPIX
EPIX was delisted on the 8th of October, 2025.
20 hedge funds and large institutions have $86.5M invested in ESSA Pharma in 2020 Q2 according to their latest regulatory filings, with 5 funds opening new positions, 4 increasing their positions, 4 reducing their positions, and 2 closing their positions.
150% more first-time investments, than exits
New positions opened: 5 | Existing positions closed: 2
53% more capital invested
Capital invested by funds: $56.6M → $86.5M (+$29.9M)
18% more funds holding
Funds holding: 17 → 20 (+3)
0% more funds holding in top 10
Funds holding in top 10: 2 → 2 (0)
0% more repeat investments, than reductions
Existing positions increased: 4 | Existing positions reduced: 4
0.94% less ownership
Funds ownership: 68.44% → 67.51% (-0.94%)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Janus Henderson Group
London,
|
+$962K |
| 2 |
OM
Opaleye Management
Boston,
Massachusetts
|
+$830K |
| 3 |
Morgan Stanley
New York
|
+$597K |
| 4 |
Renaissance Technologies
New York
|
+$179K |
| 5 |
WC
Wexford Capital
West Palm Beach,
Florida
|
+$15.6K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BI
BVF Inc
San Francisco,
California
|
-$2.07M |
| 2 |
OFM
Omega Fund Management
Boston,
Massachusetts
|
-$912K |
| 3 |
RCM
RA Capital Management
Boston,
Massachusetts
|
-$522K |
| 4 |
UBS Group
Zurich,
Switzerland
|
-$7K |
| 5 |
Royal Bank of Canada
Toronto,
Ontario, Canada
|
-$5.58K |
EPIX Hedge Fund Activity: Q2 2020 in Review
20 of the 4,888 institutional investors tracked by Wall St. Rank reported a position in ESSA Pharma (EPIX) for Q2 2020, worth a combined $86.5M — up 53% from $56.6M a quarter earlier.
Buyers outnumbered sellers: 5 funds opened new EPIX positions and 2 closed out — a net gain of 3 holders — while 4 added to existing stakes and 4 trimmed.
The largest buyer was Janus Henderson Group, adding an estimated $962K. The largest seller was BVF Inc, cutting an estimated $2.07M.
- 20 institutional investors held ESSA Pharma (EPIX) as of Q2 2020, up from 17 in Q1 2020.
- Funds reported $86.5M of ESSA Pharma stock for Q2 2020, up 53% quarter-over-quarter.
- 5 funds opened new ESSA Pharma positions in Q2 2020 and 2 closed out, a net change of +3 holders.
- The largest ESSA Pharma buyer in Q2 2020 was Janus Henderson Group, an estimated $962K added.
- The largest ESSA Pharma seller in Q2 2020 was BVF Inc, an estimated $2.07M sold.
Based on aggregated 13F filings for Q2 2020.